China Zoster Vaccine Market Research Report 2022-2031: Superior Efficacy of SHINGRIX Vaccine to Fuel Sales Growth – ResearchAndMarkets.com

0

DUBLIN–(BUSINESS WIRE)–The “Chinese Zoster Vaccine Market Survey Report 2022-2031” report has been added to from ResearchAndMarkets.com offer.

The commercial name of the shingles vaccine (recombinant shingles vaccine) is SHINGRIX, which was developed by GlaxoSmithKline. Its product was first approved in China in 2020. The shingles vaccine is suitable for adults aged 50 and over to protect against shingles (herpes zoster). The recombinant shingles vaccine has been listed on the Chinese market. As of July 2022, GlaxoSmithKline Biologicals is the sole manufacturer in China’s shingles vaccine market.

According to this market research, since shingles vaccine entered the Chinese market in 2020, its annual sales value has reached CNY 19 million (US$2.85 million) and its annual sales volume has reached nearly of 12,000 doses. The prospects for development are therefore quite good.

According to the analysis, from 2022 to 2031, as the shingles vaccine market expands, its sales will continue to grow. Compared with Merck’s Zostavax, SHINGRIX has better preventive effects and faster replacement speed. Therefore, as the shingles vaccine market share will gradually increase, the sales and sales volume will also increase.

Topics Covered:

  • The impact of COVID-19 on China’s shingles vaccine market

  • Sales Volume and Value of Zoster Vaccine in China 2020-2021

  • Sales Volume and Value of Shingles Vaccine by Regions in China 2020-2021

  • Competitive Landscape of China Zoster Vaccine Market

  • shingles vaccine price in china

  • Shingles Vaccine Price in China by Regions in China

  • Analysis of factors affecting the development of the Chinese shingles vaccine market

  • China shingles vaccine market outlook from 2022 to 2031

Main topics covered:

1 Relevant shingles vaccine concepts

1.1 Indications for shingles vaccine

1.2 Zoster Vaccine Development in China

1.3 Government approval of shingles vaccine in China

1.4 The impact of COVID-19 on Herpes Zoster Vaccine Sales in China

2 sales of shingles vaccine in China in 2020-2021

2.1 Zoster Vaccine Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Regions

2.2 Herpes Zoster Vaccine Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 China Herpes Zoster Vaccine Sales by Dosage Form in 2020-2021

2.3.1 Injection

2.3.2 Analysis of other dosage forms

3 Analysis of Key Manufacturers of Herpes Zoster Vaccines in China 2020-2021

3.1 Herpes Zoster Vaccine Major Manufacturers Market Share Analysis

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 GlaxoSmithKline Biologics

3.2.1 Company profile

3.2.2 SHINGRIX (GlaxoSmithKline Biologicals Shingles Vaccine) Sales in China

4 Shingles Vaccine Price for Different Manufacturers in China, 2021-2022

4.1 GlaxoSmithKline Biologicals (SHINGRIX)

4.2 Others

5 China Zoster Vaccine Market Outlook, 2022-2026

5.1 Influencing Factors on the Development of China Zoster Vaccine Market

5.1.1 The impact of COVID-19 on the Chinese shingles vaccine market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

Companies cited

  • GlaxoSmithKline Biologicals (SHINGRIX)

For more information on this report, visit https://www.researchandmarkets.com/r/7x9v0z

Share.

Comments are closed.